Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | RECQL | P46063 | 2/20 | 0.44 |
| ▸ | PTPRC | P08575 | 2/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Naftazone SCHEMBL4648800 | 1.00 | MEN1 (0.44) | MEN1KMT2AALDH1A1LMNAMAPT | |
| Naftazone SCHEMBL29615756 | 1.00 | MEN1 (0.44) | MEN1KMT2AALDH1A1LMNAMAPT | |
| SCHEMBL3277276 | 0.86 | KMT2A (0.50) | MEN1KMT2AALDH1A1LMNAMAPT | |
| SCHEMBL4648731 | 0.80 | KMT2A (0.39) | MEN1KMT2AKDM4EPTPRCCES1 | |
| SCHEMBL4648906 | 0.80 | KMT2A (0.39) | MEN1KMT2AKDM4EPTPRCCES1 | |
| SCHEMBL4648727 | 0.80 | KMT2A (0.39) | MEN1KMT2AKDM4EPTPRCCES1 | |
| SCHEMBL4648903 | 0.80 | KMT2A (0.39) | MEN1KMT2AKDM4EPTPRCCES1 | |
| SCHEMBL4648954 | 0.78 | PTPRC (0.33) | PTPRC | |
| SCHEMBL4648956 | 0.78 | PTPRC (0.33) | PTPRC | |
| SCHEMBL14197448 | 0.77 | MEN1 (0.50) | MEN1KMT2AALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 193 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240408090-A1 | Methods Of Treating Dyskinesia And Related Disorders | MELIOR PHARMACEUTICALS II, LLC | 2024-12-12 | — | — | US | claimed |
| US-12048697-B2 | Methods of treating dyskinesia and related disorders | MELIOR PHARMACEUTICALS II, LLC (US) | 2024-07-30 | — | — | US | claimed |
| US-20220331320-A1 | Methods Of Treating Dyskinesia And Related Disorders | MELIOR PHARMACEUTICALS II, LLC | 2022-10-20 | — | — | US | claimed |
| US-20190328736-A1 | Methods Of Treating Dyskinesia And Related Disorders | CAVALRY FUND I LP | 2019-10-31 | — | — | US | claimed |
| US-20190000784-A1 | PULSATILE RELEASE PHARMACEUTICAL COMPOSITION COMPRISING NAFTAZONE OR ONE OF ITS SALTS | CLEVEXEL PHARMA (FR) | 2019-01-03 | — | — | US | claimed |
| EP-3389642-A1 | PULSATILE RELEASE PHARMACEUTICAL COMPOSITION COMPRISING NAFTAZONE OR ONE OF ITS SALTS | Clevexel Pharma (FR) | 2018-10-24 | — | — | EP | claimed |
| CN-108697660-A | Including Naftazone or a kind of its pulse-release of medication composition of salt | 克利费赛尔制药公司 | 2018-10-23 | — | — | CN | claimed |
| WO-2017102846-A1 | PULSATILE RELEASE PHARMACEUTICAL COMPOSITION COMPRISING NAFTAZONE OR ONE OF ITS SALTS | CLEVEXEL PHARMA (FR) | 2017-06-22 | — | — | WO | claimed |
| EP-2970160-A2 | METHODS OF TREATING DYSKINESIA AND RELATED DISORDERS | Melior Discovery, Inc. (US) | 2016-01-20 | — | — | EP | claimed |
| CN-105209445-A | Methods of treating dyskinesia and related disorders | MELIOR DISCOVERY INC | 2015-12-30 | — | — | CN | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| WO-2007017768-A2 | NOVEL USES FOR DRUGS TARGETING GLUTAMINE SYNTHETASE | NEWTHERA (FR) | 2007-02-15 | — | — | WO | claimed |
| JP-2001526658-A | — | — | 2001-12-18 | — | — | JP | claimed |
| US-6221395-B1 | POORLY SOLUBLE IN WATER ACTIVE PRINCIPLE (ES: NIFEDIPINE) IS TREATED WITH A SODIUM LAURYL SULFATE SURFACTANT AND HYDROXYPROPYL METHYL CELLULOSE; HIGH BIOAVAILABILITY | JAGOTEC AG (CH) | 2001-04-24 | — | — | US | claimed |
| EP-0631776-B1 | Use of beta-naphthoquinone for accelerating the proliferation of endothelial cells and inhibition of NO synthases | HOECHST MARION ROUSSEL INC (FR) | 2000-11-22 | — | — | EP | claimed |
| EP-0631777-B1 | Use of derivatives of beta-naphthoquinone for inhibiting platelet aggregation | HOECHST MARION ROUSSEL INC (FR) | 2000-11-22 | — | — | EP | claimed |
| EP-0981339-A1 | USE OF A PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING ISCHEMIA | Remacle, José (BE) | 2000-03-01 | — | — | EP | claimed |
| WO-1998051291-A1 | USE OF A PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING ISCHEMIA | REMACLE JOSE (BE) | 1998-11-19 | — | — | WO | claimed |
| EP-0468392-A1 | Process for preparing pharmaceutical compositions having an increased active substance dissolution rate, and the compositions obtained | JAGOTEC AG (CH) | 1992-01-29 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220331320-A1 | Methods Of Treating Dyskinesia And Related Disorders | SLC6A3, CHAT, ACHE | MEN1 4331/4885KMT2A 2365/4885ALDH1A1 1203/4885 |
| US-20240408090-A1 | Methods Of Treating Dyskinesia And Related Disorders | SLC6A3, CHAT, ACHE | MEN1 4331/4885KMT2A 2365/4885ALDH1A1 1203/4885 |
| US-12048697-B2 | Methods of treating dyskinesia and related disorders | SLC6A3, CHAT, ACHE | MEN1 4331/4885KMT2A 2365/4885ALDH1A1 1203/4885 |
| US-20190328736-A1 | Methods Of Treating Dyskinesia And Related Disorders | SLC6A3, CHAT, ACHE | MEN1 4331/4885KMT2A 2365/4885ALDH1A1 1203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.